2017
Efficacy of Apremilast on Quality-of-Life Measures in Patients with Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
Bagel J, Lebwohl M, Stein Gold L, Jackson J, Goncalves J, Levi E, Callis Duffin K, Strober B. Efficacy of Apremilast on Quality-of-Life Measures in Patients with Moderate Plaque Psoriasis (UNVEIL Phase IV Study). SKIN The Journal Of Cutaneous Medicine 2017, 1: s13. DOI: 10.25251/skin.1.supp.12.Peer-Reviewed Original Research
2014
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis
Papp K, Menter A, Strober B, Kricorian G, Thompson E, Milmont C, Nirula A, Klekotka P. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. Journal Of The American Academy Of Dermatology 2014, 72: 436-439.e1. PMID: 25553889, DOI: 10.1016/j.jaad.2014.10.026.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisBiologic useHistory of PsAPlaque psoriasisDermatology Life Quality Index responseStatic Physician's Global Assessment scorePhysician Global Assessment scoreSafety of brodalumabPlacebo-controlled studySubgroup of patientsSeverity Index scoreSubpopulation of patientsGlobal assessment scoreSelf-reported historyPrior biologicsTreat populationPsoriasis AreaPsoriatic arthritisWeek 12Subset analysisNovel therapiesBrodalumabLife measuresPatientsPsoriasis